OBJECTIVE: To evaluate circulating visfatin and its relationship with disease activity and serum lipids in patients with early, treatment-naïve rheumatoid arthritis (RA). METHODS: Serum visfatin was measured in 40 patients with early RA before and after three months of treatment and in 30 age- and sex-matched healthy individuals. Disease activity was assessed using the Disease Activity Score for 28 joints (DAS28) at baseline and at three and 12 months. Multivariate linear regression analysis was performed to evaluate whether improved disease activity is related to serum visfatin or a change in visfatin level. RESULTS: Serum visfatin was significantly elevated in early RA patients compared to healthy controls (1.92±1.17 vs. 1.36±0.93 ng/ml; p = 0.034) and significantly decreased after three months of treatment (to 0.99±0.67 ng/ml; p<0.001). Circulating visfatin and a change in visfatin level correlated with disease activity and improved disease activity over time, respectively. A decrease in visfatin after three months predicted a DAS28 improvement after 12 months. In addition, decreased serum visfatin was not associated with an improved atherogenic index but was associated with an increase in total cholesterol level. CONCLUSION: A short-term decrease in circulating visfatin may represent an independent predictor of long-term disease activity improvement in patients with early RA.

Institute of Rheumatology Prague Czech Republic

Institute of Rheumatology Prague Czech Republic; Department of Rheumatology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Technology Centre ASCR Prague Czech Republic

Zobrazit více v PubMed

Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol Cell Biol 14: 1431–7. PubMed PMC

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–30. PubMed

Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, et al. (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56: 2829–39. PubMed

Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, et al. (2006) Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 54: 2084–95. PubMed

Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83: 804–16. PubMed

Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl LH, et al. (2012) Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 71: 1510–6. PubMed PMC

Présumey J, Courties G, Louis-Plence P, Escriou V, Scherman D, et al. (2013) Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Ann Rheum Dis 72: 1717–24. PubMed

Ospelt C, Gay S (2008) The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 22: 239–52. PubMed

Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, et al. (2008) The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 10: 208. PubMed PMC

Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1198–201. PubMed PMC

Rho YH, Solus J, Sokka T, Oeser A, Chung CP, et al. (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60: 1906–14. PubMed PMC

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Berja A, Miranda-Filloy JA, et al. (2010) Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 28: 56–62. PubMed

Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, et al. (2011) Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 63: 2567–74. PubMed

Senolt L, Krystufkova O, Hulejova H, Kuklova M, Filkova M, et al. (2011) The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine 55: 116–21. PubMed

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580–8. PubMed

Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, et al. (2005) Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 834–8. PubMed PMC

El-Hini SH, Mohamed FI, Hassan AA, Ali F, Mahmoud A, et al. (2013) Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients. Rheumatol Int 33: 2283–9. PubMed

Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, et al. (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26: 311–6. PubMed

Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, et al. (2008) High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 26: 596–603. PubMed

Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 27: 515–27. PubMed

Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, et al. (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62: 842–5. PubMed PMC

MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis